Transdermal drug delivery systems and skin sensitivity reactions: Incidence and management

American Journal of Clinical Dermatology

Volumn 1, Issue 6, 2000, Pages 361-368

  Murphy, Michelle ^a   Carmichael, Andrew J ^a  

^a JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG DELIVERY SYSTEM; DRUG ERUPTION; HUMAN; INSTRUMENTATION; INTRADERMAL DRUG ADMINISTRATION; REVIEW;

ADMINISTRATION, CUTANEOUS; DRUG DELIVERY SYSTEMS; DRUG ERUPTIONS; HUMANS;

EID: 0034331266     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200001060-00004     Document Type: Review

References (73)

1. Shaw JE, Urquhart J. Transdermal drug administration - a nuisance becomes an opportunity. BMJ 1981; 283: 875-6
2. Scheuplein RJ, Blank IH. Permeability of the skin. Physiologic Rev 1971; 51: 702-47
3. Brown L, Langer R. Transdermal delivery of drugs. Ann Rev Med 1988; 39: 221-9
4. Muller P, Imhof PR, Burkart F, et al. Human pharmacological studies of a new transdermal system containing nitroglycerin. Eur J Clin Pharmacol 1982; 22: 473-80
5. Hadgraft J. Advances in transdermal drug delivery. Practitioner 1995; 240: 656-8
6. Hurkmans JFGM, Bodde HE, van Driel LMJ, et al. Skin irritation caused by transdermal drug delivery system during long-term (5 days) application. Br J Dermatol 1985; 112: 461-7
7. Utian WH. In discussion: Judd H, Ravaikar V, Utain WH, Lawrence W. Panel discussion III. Am J Obstet Gynecol 1987; 156: 1338-41
8. Bircher AJ, Howald H, Rufli TH. Adverse skin reactions to nicotine in a transdermal therapeutic system. Contact Dermatitis 1991: 25: 230-6
9. Homick JL, Kohl RL, Reschke MF, et al. Transdermal scopolamine in the prevention of motion sickness: evaluation of the time course of efficacy. Aviat Space Environ Med 1983; 54: 994-1000
10. Lindburg M, Forslind B. The effects of occlusion of the skin on the Langerhan's' cell and the epidermal mononuclear cells. Acta Dermato-Venerologica (Stockholm) 1981; 61: 201-5
11. Nieboer C, Bruynzeel DP, Boorsma DM. The effect of occlusion of the skin with the transdermal therapeutic system on Langerhans' cells and the induction of skin irritation. Arch Dermatol 1987; 123: 1499-502
12. Fisher AA. Dermatitis due to transdermal therapeutic systems. Cutis 1984; 34: 87-8
13. Murray KB. Hazard of microwave ovens to transdermal delivery system. N Engl J Med 1984; 310: 721
14. Wrenn K. The hazards of defibrillation through nitroglycerin patches. Ann Emerg Med 1990; 19: 1327-8
15. Kligman AM. The identification of contact allergens by human assay: III. The maximization test: a procedure for screening and rating contact sensitizers. J Investigative Dermatol 1966; 47: 393-409
16. Price NM, Schmitt LG, McGuire J, et al. Transdermal scopolamine in the prevention of motion sickness at sea. Clin Pharmacol Ther 1981; 29: 313-418
17. Popli S, Daugirdas JT, Neubauer JA, et al. Transdermal clonidine in mild hypertension. Arch Intern Med 1986; 146: 2140-4
18. Scheper RJ, von Blomberg BME, De Groot J, et al. Low allergenicity of clonidine impedes studies of sensitization mechanisms in guinea pig models. Contact Dermatitis 1990; 23: 81-9
19. Trozak DJ. Delayed hypersensitivity to scopolamine delivered by a transdermal device. J Am Acad Dermatol 1985; 13: 247-51
20. Gordan CR, Shupak A, Doweck I, et al. Allergic contact dermatitis caused by transdermal hyoscine. BMJ 1989; 298: 1220-1
21. Dick JBC, Northridge DB, Lawson AAH. Skin reactions to long-term transdermal clonidine. Lancet 1987; I: 516
22. Harari Z, Sommer I, Knobel B. Multifocal contact dermatitis to Nitroderm TTS5 with extensive postinflammatory hypermelanosis. Dermatologica 1987; 174: 249-52
23. Carmichael AJ, Foulds IS. Allergic contact dermatitis from transdermal nitroglycerin. Contact Dermatitis 1989; 21: 113-4
24. White TM, Guidry JR. Rebound hypertension associated with transdermal clonidine and contact dermatitis. West J Med 1986; 145: 104
25. Chandraratna PAN, O'Dell RE. Allergic reactions to nitroglycerin ointment: report of five cases. Curr Ther Res 1987; 42: 481-4
26. Hollifield J. Clinical acceptability of transdermal clonidine: a large-scale evaluation by practitioners. Am Heart J 1986; 112: 900-6
27. Maibach HI. Oral substitution in patients sensitized by transdermal clonidine treatment. Contact Dermatitis 1985; 12: 192-5
28. Goncalo M, Oliveria HS, Monterio C, et al. Allergic and systemic contact dermatitis from estradiol. Contact Dermatitis 1999; 40: 58
29. Kelly HW. Controlled-release transdermal drug delivery. Cutis 1985; 35: 204-5
30. van der Willigen AH, deGraaf YP, van Joost TH. Peri-ocular dermatitis from atropine. Contact Dermatitis 1987; 17: 55-6
31. Hendricks AA, Jr Dec GW. Contact dermatitis due to nitroglycerin ointment. Arch Dermatol 1979; 115: 853-5
32. Sausker WF, Frederick FD. Allergic contact dermatitis secondary secondary to topical nitroglycerin. J Am Med Assoc 1978; 239: 1743-4
33. Apted J. Percutaneous nitroglycerin patches. Med J Aust 1988; 148: 482
34. Rosenfield AS, White WB. Allergic contact dermatitis secondary to transdermal nitroglycerin. Am Heart J 1984; 108: 1061-2
35. Topaz O, Abraham D. Severe allergic contact dermatitis secondary to nitroglycerin in a transdermal therapeutic system. Ann Allergy 1987; 59: 365-6
36. Place VA, Powers M, Darley PE, et al. A double-blind comparative study of Estraderm and Premarin in the amelioration of postmenopausal symptoms. Am J Obstet Gynecol 1985; 152: 1092-9
37. Fisher AA. Contact dermatitis: highlights from the 1987 Meeting of the American Academy of Dermatology, San Antonio, Texas. Cutis 1988; 41: 87-8
38. Schwartz BK, Clendenning WE. Allergic contact dermatitis from hydroxypropyl cellulose in a transdermal estradiol patch. Contact Dermatitis 1988; 18: 106-7
39. Corazza M, Virgili A, Mantovani L, et al. Propylene glycol allergy from acyclovir cream with cross-reactivity to hydroxypropyl cellulose in a transdermal estradiol system? Contact Dermatitis 1993; 29 283-4
40. Ducros B, Bonnin JP, Navaranne A, et al. Eczema due to contact with ethanol in oestradiol transdermal patch (Estraderm TTS 50). Nouvelles Dermatologiques 1989; 8: 21-2
41. Grebe SKG, Adams JD, Feek CM. Systemic sensitization to ethanol by transdermal estrogen patches. Arch Dermatol 1993; 129: 379-80
42. McBurney EI, Noel SB, Collins JH. Contact dermatitis to transdermal estradiol system. J Am Acad Dermatol 1989; 20: 508-10
43. Carmichael AJ, Foulds IS. Allergic contact dermatitis to oestradiol in oestrogen patches. Contact Dermatitis 1992; 26: 194-5
44. El Sayed F, Bayle-Lebey P, Marguery MC, et al. Systemic sensitization to 17 beta-oestradiol induced by transcutaneous administration. Ann Dermatol Venereol 1996; 123 (1): 26-8
45. Nicotine patches [editorial]. Drugs Ther Bull 1993; 31: 95-6
46. Abelin T, Buchler A, Muller P, et al. Controlled trial of transdermal nicotine patch in tobacco withdrawal. Lancet 1989; I: 7-10
47. Russell MAH, Stapleton JA, Feyerabend C, et al. Targeting heavy smokers in general practice: randomised controlled trial of transdermal nicotine patches. BMJ 1993; 306: 1308-12
48. Gourlay SG, Forbes A, Marriner T, et al. Predictors and timing of adverse experiences during transdermal nicotine therapy. Drug Saf 1999; 20 (6): 545-55
49. Farm G. Contact allergy to nicotine from a nicotine patch. Contact Dermatitis 1993; 29: 214-5
50. Dwyer CM, Forsyth A. Allergic contact dermatitis from methacrylates in a nicotine transdermal patch. Contact Dermatitis 1994; 30: 309-10
51. Bircher AJ, Havald H, Rufli T. Adverse reactions to nicotine in a transdermal therapeutic system. Contact Dermatitis 1991; 25: 230-6
52. von Bahr B, Wahlberg JE. Reactivity to nicotine patches wrongly blamed on contact allergy. Contact Dermatitis 1997; 37: 44
53. Mills CM, Hill SA, Marks R. Transdermal nicotine suppresses cutaneous inflammation. Arch Dermatol 1997; 133 (7): 823-5
54. Boekhorst JC. Allergic contact dermatitis with transdermal clonidine. Lancet 1983; II: 1031-2
55. Falkner B, Thanki B, Lowenthal DY. Trandermal clonidine in the treatment of adolescent hypertension. J Hypertens 1985; 3 Suppl. 4: 61-3
56. Horning JR, Zawada Jr ET, Simmons JL, et al. Efficacy and safety of two-year therapy with transdermal clonidine for essential hypertension. Chest 1988; 93: 941-5
57. Weber MA. Transdermal antihypertensive therapy: clinical and metabolic considerations. Am Heart J 1986; 112: 906-12
58. McMahon FG, Weber MA. Allergic skin reactions to transdermal clonidine. Lancet 1983; II: 851
59. Transdermal antihypertensive drugs [editorial]. Lancet 1987; I: 79-80
60. White TM, Guidry JR. Rebound hypertension associated with transdermal clonidine and contact dermatitis. Western J Med 1986; 145: 104
61. Groth H, Vetter H, Knuesel J, et al. Allergic skin reactions transdermal clonidine. Lancet 1883; II: 850-1
62. Ahmedzai S, Brooks D. Transdermal fentanyl versus sustained release oral morphine in cancer pain: preference, efficacy and quality of life. J Pain Symptom Manage 1997; 13 (5): 254-61
63. Stoukides CA, Stegman M. Diffuse rash associated with transdermal fentanyl. Clin Pharm 1992; 11 (3): 222
64. Androderm® Testosterone Transdermal System prescribing information, SmithKline Beecham Pharmaceuticals, Philadelphia (PA), May 1997
65. Bennett NJ. A burn-like lesion caused by a testosterone transdermal system. Burns 1998; 25 (5): 478-80
66. Wilson DE, Kaidbey K, Bouke SC, et al. Use of topical corticosteroid pretreatment to reduce the incidence and severity of skin reactions associated with testosterone transdermal therapy. Clin Ther 1998; 20 (2): 299-306
67. Buckley DA, Wilkinson SM, Higgens EM. Contact allergy to a testosterone patch. Contact Dermatitis 1999; 39: 91-2
68. Nater JP, Degroot AC, editors. Unwanted effects of cosmetics and drugs used in dermatology. 2nd ed. Amsterdam: Elsevier, 1985: 60
69. Gratten CEH, Kennedy CTC. Allergic contact dermatitis to transdermal clonidine. Contact Dermatitis 1985; 12: 225-6
70. Magnusson B, Kligman AM. Allergic contact dermatitis in the guinea pig: identification of contact allergies. Springfield (IL): Charles C Thomas, 1986: 60-1
71. Ross D, Rees M, Godfree V, et al. Randomised crossover comparison of skin irritation with two transdermal oestradiol patches. BMJ 1997; 315 (7103): 288
72. Berth JJ, Lipsky JJ. Transcutaneous drug delivery: a practical review. Mayo Clin Proc 1995; 70: 581-6
73. Amkraut AA, Jordan WP, Taskovich L. Effect of coadministration of corticosteroids on the development of contact sensitization. J Am Acad Dermatol 1996; 35: 27-31